Reported Saturday, ITeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High...
Reported Saturday, ITeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High...
愛文思控股週六報告，宣佈由GSK贊助的GALAXIES Lung-201階段2平台研究的隨訪中期數據，針對PD-L1高表達的未經治療、不可切除、局部晚期或轉移性患者的Belrestotug+Dostarlimab雙聯療法。
Reported Saturday, ITeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High Non-small Cell Lung Cancer
週六報道，iteos therapeutics宣佈了GSK贊助的GALAXIES Lung-201二期平台研究的後續中期數據，該研究針對未經治療、不可切除、局部晚期或轉移性PD-L1高表達的非小細胞肺癌患者進行了Belrestotug + Dostarlimab的雙聯方案。
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose.
- >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy.
- Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations.
- GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting
- Belrestotug + Dostarlimab組合療法觀察到63.3-76.7%的臨床有意義的客觀反應率（ORR），不同劑量下的確認ORR（cORR）約爲60%。
- Belrestotug + Dostarlimab與Dostarlimab單藥相比，確認ORR差異超過30%。
- Belrestotug + Dostarlimab的安全性與已知的檢查點抑制劑聯合治療的安全性基本一致。
- GALAXIES Lung-301是全球範圍內的三期註冊研究，正在招募同一適應症和環境的患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。